Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

TSXV:ARCH - Post Discussion

Arch Biopartners Inc > Huge Upside Potential Here
View:
Post by TheBearInTheWoods on Nov 23, 2021 10:07pm

Huge Upside Potential Here

$ARCH.V is literally waiting on third party reviews of its Phase II data that has an unmet market of 20 billion a year. It has a full mechanism of action patents and a library of 8 drugs with the technology about to be potentially verified.

Phase I - 98% Failure rate 
Phase II - 85% Failure rate 
Phase III - 34% Failure rate 

This is a huge derisking opportunity!!
Comment by Antonius2 on Nov 24, 2021 5:40pm
The phase II trial results are being signalled by the lack of insider stock selling.
Comment by GoldenArm on Nov 25, 2021 11:17am
I just sold an oil stock, which did well for me, and bought double what I had. I don't hold a significant percentage like other says they do but I like everything about this company when I bought it for $1.39/shr 6 months ago.
Arch Biopartners Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities